Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials

医学 伦瓦提尼 阿替唑单抗 索拉非尼 内科学 肿瘤科 贝伐单抗 临床终点 危险系数 卡波扎尼布 肝细胞癌 无容量 无进展生存期 肾细胞癌 置信区间 临床试验 癌症 总体生存率 免疫疗法 化疗
作者
Claudia Angela Maria Fulgenzi,Antonio D’Alessio,Chiara Airoldi,Lorenza Scotti,Coşkun Özer Demirtaş,Alessandra Gennari,Alessio Cortellini,David J. Pinato
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:174: 57-67 被引量:39
标识
DOI:10.1016/j.ejca.2022.06.058
摘要

Dual programmed cell death-1 and vascular endothelial growth factor pathway inhibition is the novel standard of care for patients with unresectable hepatocellular carcinoma. Direct comparisons between first-line treatments are lacking.We conducted a literature search in MEDLINE (https://pubmed.ncbi.nlm.nih.gov), the Cochrane library (https://www.cochranelibrary.com) and Embase (www.embase.com) between January 2007 and February 2022. We included phase III randomised controlled trials that tested immune-checkpoint inhibitors or tyrosine kinase inhibitors, including sorafenib, lenvatinib and donafenib, and evaluated as primary end-point overall survival (OS) or progression-free survival (PFS). Studies testing loco-regional therapies were excluded. The primary end-point was to compare the efficacy of first-line options in terms of OS and PFS. We extracted Hazard ratios (HR) and 95% confidence intervals (95% CI) for OS and PFS and performed a frequentist network meta-analysis with fixed effect multivariable meta-regression models. The research protocol was registered in PROSPERO, an international prospective register of systematic reviews (registration code CRD42022312489).Literature review yielded 13709 results, after duplicates removal and exclusion of not relevant studies, 70 papers were available for screening. After full-text review, 9 studies were eligible for analysis. Atezolizumab plus bevacizumab reduced the risk of death compared to placebo (HR 0·40; 95% CI 0·28-0·57), sorafenib (HR 0·58; 95% CI 0·42-0·80), lenvatinib (HR 0·63; 95% CI 0·44-0·89), atezolizumab plus cabozantinib (HR 0·64; 95% CI 0·43-0·97), nivolumab (HR 0·68; 95% CI 0·48-0·98) and donafenib (HR 0·69; 95% CI 0·48-0·99). Atezolizumab plus bevacizumab was not statistically superior to durvalumab plus tremelimumab (HR 0·74; 95% CI 0·52-1·06) and sintilimab plus IBI305 (HR 1·02; 95% CI 0·67-1·55) in reducing the risk of death. Efficacy was associated with a higher risk of grade 3 adverse events.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
万能图书馆应助gs采纳,获得10
刚刚
刚刚
刚刚
wll1091完成签到 ,获得积分10
1秒前
1秒前
zxm完成签到,获得积分10
1秒前
1秒前
若水完成签到,获得积分10
2秒前
2秒前
烟柳画桥完成签到,获得积分10
2秒前
wlj完成签到 ,获得积分10
2秒前
2秒前
陈秋发布了新的文献求助20
3秒前
chen发布了新的文献求助10
3秒前
3秒前
3秒前
佐佐的2xL完成签到,获得积分10
4秒前
4秒前
Carly发布了新的文献求助10
4秒前
华仔应助无昵称采纳,获得10
4秒前
LISHAN完成签到,获得积分10
5秒前
5秒前
甘乐发布了新的文献求助30
5秒前
5秒前
领导范儿应助Li采纳,获得10
6秒前
搞怪便当完成签到,获得积分10
6秒前
6秒前
yuxx发布了新的文献求助10
6秒前
Foliage发布了新的文献求助10
6秒前
怡然的雪柳完成签到,获得积分10
7秒前
姣妹崽完成签到,获得积分10
7秒前
7秒前
华仔应助ji采纳,获得10
8秒前
FXQ123_范完成签到,获得积分10
8秒前
迷人书蝶完成签到,获得积分10
9秒前
9秒前
烟花应助荡乎宇宙如虚舟采纳,获得30
9秒前
健壮凡桃发布了新的文献求助10
10秒前
10秒前
俊哥发布了新的文献求助10
10秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968964
求助须知:如何正确求助?哪些是违规求助? 3513877
关于积分的说明 11170569
捐赠科研通 3249201
什么是DOI,文献DOI怎么找? 1794692
邀请新用户注册赠送积分活动 875297
科研通“疑难数据库(出版商)”最低求助积分说明 804755